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Abstract
Hypertension is frequently diagnosed among patients with chronic kidney disease (CKD) and often remains poorly 
controlled in end stage kidney disease (ESKD) especially in haemodialysis patients. These patients are characterized 
by higher blood pressure variability than the general population. Volume overload is a primary factor contributing 
into the pathogenesis of hypertension in this cohort. In the diagnosis and monitoring of hypertension in haemo-
dialysis patients with chronic kidney disease self-measured of blood pressure at home done during the days between 
haemodialysis sessions should be considered. Home blood pressure measurements are of greater prognostic value 
than haemodialysis unit recording. Target-values of blood pressure in haemodialysis patients are still matter of de-
bate. However, self-measured systolic blood pressure values at home between 120 to 130 mmHg are associated with 
the best prognosis in haemodialysis patients with CKD. Among not pharmacological methods of antihypertensive 
treatment in haemodialysis patients with CKD reducing volaemia by increasing ultrafiltration during haemodialysis 
procedures, individualization of sodium concentration in the dialysis fluid and low sodium diet should be listed. 
While, in the pharmacotherapy b-adrenergic antagonists seem to be the drugs of first choice.
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Streszczenie
U chorych z przewlekłą chorobą nerek (PChN) często występuje nadciśnienie tętnicze. U wielu chorych z PChN 
leczenie nadciśnienia tętniczego nie jest w pełni skuteczne. Dotyczy to szczególnie chorych ze schyłkową niewy-
dolnością nerek leczonych hemodializami. Chorzy ci charakteryzują się również większą zmiennością ciśnienia tęt-
niczego niż populacja ogólna. Głównym czynnikiem w patogenezie nadciśnienia tętniczego u chorych ze schyłkową 
niewydolnością nerek leczonych hemodializami jest hiperwolemia. W rozpoznawaniu i monitorowaniu nadciśnienia 
tętniczego u tych chorych należy preferować wykonywanie samodzielnych domowych pomiarów ciśnienia tętniczego 
w dniach bez zabiegów hemodializy. Domowe pomiary ciśnienia tętniczego mają większą wartość prognostyczną 
niż pomiary ciśnienia tętniczego wykonywane w stacji dializ. Docelowe wartości ciśnienia tętniczego u chorych ze 
schyłkową niewydolnością nerek leczonych hemodializami są nadal przedmiotem kontrowersji. Wykazano jednak, że 
najlepszym rokowaniem charakteryzują się chorzy ze skurczowym ciśnieniem tętniczym wynoszącym w samodziel-
nych domowych pomiarach 120–130 mm Hg. Niefarmakologicznymi metodami leczenia przeciwnadciśnieniowego 
arterial hypertension 2017, vol. 21, no. 4
196 www.ah.viamedica.pl
u chorych ze schyłkową niewydolnością nerek leczonych hemodializami są: zmniejszenie wolemii przez zwiększenie 
ultrafiltracji w trakcie hemodializy, indywidualizacja stężenia sodu w płynie dializacyjnym oraz zmniejszenie zawar-
tości sodu w diecie. W farmakoterapii lekami pierwszego wyboru są antagoniści receptorów b-adrenergicznych.
Słowa kluczowe: nadciśnienie tętnicze, hemodializa, przewlekła choroba nerek
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Introduction
Hypertension is highly prevalent in patients with 
chronic kidney disease (CKD), particularly in pa-
tients with end-stage kidney disease (ESKD) treated 
with haemodialysis [1, 2] and it is the important 
risk factor contributing to the high cardiovascular 
morbidity and mortality in this population [3, 4]. 
In the early years of renal replacement therapy with 
haemodialysis, hypertension requiring pharmaco-
logic therapy was seen only in 10% to 15% of 
the patients, most probably due to strict patients’ 
selection, dialysate and dietary sodium restriction, 
attention to dry-weight and longer time of haemo-
dialysis sessions [5]. However, more recent data sug-
gest that the prevalence of hypertension in patients 
on chronic haemodialysis exceeds the number seen 
in the general population [6] or those with CKD 
not required haemodialysis [7]. Although, nowadays 
hypertension is present in 50% to 90% of patients 
on haemodialysis [8–10], it remains a controversial 
prognostic marker in patients with CKD stage 5. In 
patients receiving chronic haemodialysis, approxi-
mately 45% of overall mortality is attributable to 
the cardiac disease. Acute complications of coro-
nary heart disease in patients with renal dysfunction 
account only 20% of cardiac deaths [11]. In these 
patients cardiovascular diseases are more likely to 
manifest as calcification of the coronary arteries me-
dia [12, 13], left ventricular hypertrophy [14, 15], 
and sudden cardiac death [16]. In contrast to the 
guidelines for the general population, in which sys-
tolic blood pressure of ≤ 140 mmHg is considered 
the treatment target, a debate remains regarding the 
target blood pressure in haemodialysis patients [17]. 
Hypertension in haemodialysis patients is an unique 
diagnostic, prognostic and therapeutic challenge [18]. 
The main aim of this review is to systematize the 
current state of knowledge concerning hypertension 
in haemodialysis patients, especially pathophysiolo-
gy, variability, measurement methods, target-values 
of blood pressure, and mode of antihypertensive 
treatment.
Pathophysiology of hypertension in 
haemodialysis patients
The pathogenesis of hypertension in ESKD pa-
tients include increased extracellular volume, in-
creased sympathetic and renin-angiotensin-aldoste-
rone (RAA) systems activity, secondary hyperpara-
thyroidism, endothelial cell dysfunction, increased 
oxidative stress and exposure to erythropoiesis-sti-
mulating agents (ESAs) [19] (Table I).
Volume overload is the main factor participating 
in the pathogenesis of arterial hypertension in dialy-
sis patients [20, 21]. The inability to excrete sodium 
and water via failured kidney contributes to increased 
extracellular volume, increased cardiac output and, as 
a consequence, increased blood pressure in haemodia - 
lysis patients.
The inadequate activity of RAA system has long 
been implicated in the etiology of hypertension in 
haemodialysis patients [19]. In a study of 51 haemo-
dialysis patients, there were significant differences 
in the plasma renin activity (PRA) between normo-
tensive subjects (n = 9), hypertensive subjects whose 
blood pressure was controlled by ultrafiltration and 
dietary sodium restriction (n = 24), and subjects with 
persistent hypertension (n = 18) [22]. PRA was the 
lowest in the normotensive group, significantly high-
er in the group with controlled hypertension, and 
table I. Causes of hypertension in haemodialysis patients with 
chronic kidney disease
Causes of hypertension in haemodialysis patients with chronic 
kidney disease
Increased extracellular volume — volume overload
Increased sympathetic nervous system activity





Exposure to erythropoiesis — stimulating agents (ESAs)
Patrycja Pokora et al. Pathogenesis and treatment of hypertension in haemodialysis patients with chronic kidney disease
197www.ah.viamedica.pl
the highest in the persistently hypertensive group. 
In 17 out of 18 persistently hypertensive subjects, 
bilateral nephrectomy resulted in significant reduc-
tions in blood pressure. Post-nephrectomy PRA was 
measured in 12 subjects, and was significantly low-
er, suggesting that elevated baseline PRA may have 
contributed to the poorly controlled hypertension. 
Angiotensin II and aldosterone which are primary 
mediators of RAA system, both contribute to left 
ventricular hypertrophy (LVH) and endothelial cell 
dysfunction independently of blood pressure [19]. 
Patients with ESKD are characterized by higher 
sympathetic nervous system (SNS) activity (mea-
sured by skeletal muscle sympathetic nerve activity 
[MSNA]), mean arterial blood pressure, and vascular 
resistance than healthy controls, or CKD stage 5 
patients who have had bilateral nephrectomy [23]. 
Furthermore, in renal transplant recipients, MSNA 
remained elevated following renal transplantation, 
but subsequently decreased following native kidneys 
nephrectomy. It suggests that it is not uraemia per se, 
but rather signaling from diseased kidneys that re-
sults in elevated MSNA and hypertension. However, 
while the initial trigger for increased SNS activity is 
likely renal ischaemia with a consequential increase of 
renal afferent nerve activation, other mediators that 
are also affected by CKD stage 5 such as nitric oxide, 
angiotensin II, and superoxide and may further mod-
ify blood pressure. Nocturnal decrease of blood pres-
sure is frequently absent in patients with CKD and 
it is associated with adverse outcomes [24]. There is 
evidence that more frequent haemodialysis sessions, 
whether through increased removal of uremic toxins 
or improvement of volume status, may lower SNS 
activity. In a study of stable non-diabetic haemodia-
lysis patients whose blood pressure was controlled 
with or without antihypertensive drugs, conversion 
from standard three times a  week (12h/week total 
HD time) to haemodialysis six times a week (12h/ 
/week total HD time) resulted in significant reduc-
tion in ambulatory blood pressure (systolic and di-
astolic) and MSNA. The subjects who had stud-
ies repeated following conversion back to standard 
haemodialysis regimen demonstrated an increase in 
MSNA back to baseline values [25].
The secondary hyperparathyroidism that accom-
panies CKD may contribute to the high prevalence 
of hypertension in these patients. The evidence based 
on a retrospective study in CKD patients demonstrat-
ing that systolic and diastolic blood pressure were sig-
nificantly increased in subjects with increased plasma 
concentration of parathyroid hormone (PTH) [26]. 
Furthermore, a possible mechanism was suggested by 
the findings of increased platelet cytosolic calcium in 
the group with increased PTH plasma concentration. 
Mean blood pressure correlated highly significant 
with cytosolic calcium and plasma PTH concentra-
tion. Treatment with active vitamin D (alfacalcidol) 
significantly lowered plasma PTH level, and mean 
blood pressure. Kuczera et al. observed a decrease of 
blood pressure in haemodialysis patients with chron-
ic kidney disease and secondary hyperparathyroidism 
treated with calcimimetic cinacalcet [27]. These ob-
servations were confirmed recently in the analysis of 
the results from EVOLVE study [28].
Erythropoiesis-stimulating agents used to correct 
the anaemia associated with CKD may also lead to 
blood pressure increase [29]. The proposed mecha-
nisms specific to haemodialysis patients include in-
crease of ET-1 release and increased sensitivity to 
angiotensin II and adrenergic stimuli. The effect of 
blood pressure is dependent on the dose, but not 
necessary the pre-treatment blood pressure as both 
previously normotensive and hypertensive patients 
can have ESAs related blood pressure increase [19]. 
Blood pressure variability among 
haemodialysis patients
In the majority of HD patients (85%) decrease of 
blood pressure during haemodialysis procedures is ob-
served [30]. Agarwal et al. observed that home BP 
increases over time after haemodialysis treatment and 
this relationship was non-linear and reach plateau after 
approximately 2 days. It is important to stress that 
probing dry-weight does not perturb the time-depen-
dent relationship of home BP but steepens the slope 
for ambulatory BP. Increase in interdialytic weight gain 
reduces the intercept BP but steepens the slope of 
BP changes. Furthermore, the timing of home BP 
monitoring influences the accuracy and precision of 
the measurements and the time elapsed after dialysis 
must to be considered in interpreting the home BP 
recordings in haemodialysis patients [31]. Taking into 
account facts mentioned above, it should be stated that 
blood pressure in haemodialysis patients is characterized 
by high variability. In fact, variability in blood pressure 
within patients is similar to that between patients [32]. 
The percentage of interdialytic weight gain (over-
all weight gain/estimated dry weight x 100) predicts 
increased pre-HD systolic blood pressure and greater 
reduction in systolic blood pressure from pre- to 
post-HD, particularly in non-diabetics, younger pa-
tients, and those with greater estimated dry weight 
[33]. In one large, observational study, increased in-
terdialytic weight gain (IDWG) was associated with 
increased mortality [34].
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table II. Methods of blood pressure measurement in haemodialy-
sis patients
Methods of measuring blood pressure in haemodialysis patients:
Home blood pressure monitoring — HBPM
Automatic 44-hour recording blood pressure — Ambulatory BP 
Monitoring
Measurements done before and after haemodialysis — Dialysis Unit 
Blood Pressure
In the minority of HD patients (15%) blood pres-
sure increases during haemodialysis [30]. The main 
cause of blood pressure increase in these patients 
is the increase of vascular resistance. Using cardiac 
output estimated from echocardiograms and blood 
pressure measurements before and after haemodia-
lysis, it was found there was a significant increase in 
vascular resistance from pre- to post-haemodialysis 
in the intradialytic hypertension patients compared 
to patients whose blood pressure did not increase 
during haemodialysis. There were no significant dif-
ferences in the change in cardiac output (or in the 
individual pre- or post-dialysis measurements) be-
tween the 2 groups. These authors and others have 
sought to identify specific mediators of the increase 
in blood pressure that may be related to over secre-
tion of endogenous vasoconstrictive substances. In 
the study by Chou et al. [35], there was no evidence 
that surges in sympathetic nervous system activity 
(assessed using plasma catecholamines) or in RAA 
system activity (assessed using plasma renin activity) 
could explain such an increase in vascular resistance. 
They did find, however, imbalances in endothelial 
cell-derived mediators after dialysis in the intradia-
lytic hypertension patients. Specifically, there were 
higher plasma concentration of the vasoconstrictor 
— endothelin-1 (ET-1) and lower concentration ra-
tios of the vasodilator nitric oxide to ET-1. Other 
studies have investigated changes in ET-1 during di-
alysis in intradialytic hypertension and found sugges-
tive, but not confirmatory evidence, to support this 
hypothesis. Raj et al. [36] found decreases in ET-1 
in hypotension-prone patients with a  trend toward 
increases in ET-1 in the intradialytic hypertension 
group. El-Shafey et al. [37] found increased plasma 
ET-1 concentration in intradialytic hypertension pa-
tients. Based on the evidence that vasoconstriction 
may be a predominant mechanism for intradialytic 
hypertension and that ET-1 has been implicated as 
a  causative mediator for this, further investigation 
has to be directed toward the overall role of endothe-
lial cell dysfunction in intradialytic hypertension. It 
was found that patients with intradialytic hyperten-
sion had lower flow-mediated vasodilation [38]. This 
assessment of endothelial cell function occurred on 
a non-haemodialysis day so it was not influenced by 
the haemodialysis procedure. The intradialytic hy-
pertension patients also had lower number of circu-
lating endothelial progenitor cells than the controls. 
It is suggested that circulating endothelial progenitor 
cells number is a marker of cardiovascular risk (low-
er number indicates higher risk) [39]. These were 
measured prior to dialysis, so that they also were not 
influenced by the haemodialysis procedure. It is of 
note that in the Inrig et al. study [38], the change of 
plasma ET-1 concentration from pre- to post-hae-
modialysis was not different between the intradialytic 
hypertension patients and haemodialysis controls. 
So, while endothelial cell dysfunction appears to 
be more pronounced in intradialytic hypertension 
patients, the most recent research has focused on 
specific mechanisms, by which the endothelial cells 
influence intradialytic blood pressure [40].
How to measure blood pressure in chronic  
kidney disease patients on haemodialysis?
Among the features of the ideal method of mea-
suring blood pressure simplicity and low cost, reli-
able diagnosis of hypertension, prognostic value in 
assessing the risk of organ damage and prognostic 
significance should be listed. There are several meth-
ods of blood pressure measurement in haemodialy-
sis patients with chronic kidney disease: automatic 
44-hour recording of blood pressure (Ambulatory 
BP Monitoring — ABPM), not standardized mea-
surements done before and after haemodialysis, stan-
dardized measurements done before and after hae-
modialysis (Dialysis Unit Blood Pressures) and indi-
vidual measurements (at home) performed between 
haemodialysis procedures (Home BP Monitoring) 
(Table II). The identification and treatment of hy-
pertension in CKD has to face peculiar problems 
because of the marked alterations in 24-hour blood 
pressure (BP) profile, in particular of a reduced BP 
dipping at night, and the high prevalence of specific 
hypertension phenotypes, such as white coat hyper-
tension (WCH), masked hypertension (MH) [41], 
hypertension caused by fear of haemodialysis or of 
puncture a needle. 
Taking into account already discussed high blood 
pressure variability in haemodialysis patients, the 
automatic 44-hour recording of blood pressure 
(ABPM) is a  “gold standard” among methods of 
measuring blood pressure in haemodialysis patients 
with chronic kidney disease. ABPM extended to 
44-hour in comparison to 24-hour covers the whole 
mid-week dialysis interval [18]. This method is also 
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helpful in identifying patients without physiological 
nocturnal decrease of blood pressure (dipping pat-
tern) and has a prognostic value in assessing the risk 
of left ventricular hypertrophy [42]. Unfortunately, it 
is expensive and its acceptance by the patients is low.
Another method of blood pressure monitoring 
is non-standardized measurements done before and 
after haemodialysis. It is a  routine clinical prac-
tice characterized by low cost and great simplicity. 
However, a  low consistence between not standard-
ized monitoring of blood pressure and automatic 
44-hour recording of blood pressure is observed [43]. 
Agarwal et al. reported a 13.5 mmHg increase of sys-
tolic blood pressure in the measurement performed 
directly before haemodialysis [43]. Blood pressure 
measured before and after dialysis does not correlate 
well with those recorded outside the dialysis unit [44]. 
BP assessed before and after dialysis, even if obtained 
using standardized methods, correlates poorly with 
interdialytic ambulatory BP [43, 45]. Khangura et 
al. reported that blood pressure measured before hae-
modialysis had no significant prognostic value for 
risk of left ventricular hypertrophy [47]. In contrast, 
BP assessed outside the dialysis unit, whether ob-
tained by interdialytic automatic BP measurement, 
or self-measured BP at home is useful in diagnosing 
left ventricular hypertrophy [42]. Thus, dialysis unit 
measurement is only distantly related to ambulatory 
BP, or target organ damage. This poor relationship 
calls into question the use of BP obtained before 
and after dialysis for the diagnosis and treatment of 
hypertension among patients on haemodialysis [46]. 
Among the methods used in dialysis unit it is 
also possible to do standardized measurements before 
and after haemodialysis. In this method the blood 
pressure is measured in a  quiet and warm room, 
after 5 minutes of rest. Then, the arithmetic average 
of three consecutive measurements (taken every few 
minutes) should be calculated. Although this method 
is also characterized by great simplicity, to use it in 
everyday clinical practice in dialysis units would re-
quire multiplying the number of employees and thus 
would significantly increase the cost. However, stan-
dardized measurements taken after haemodialysis are 
more consistent with automatic 44-hour recording of 
blood pressure than not standardized measurements 
taken before and after haemodialysis [42].
The last method used for the assessment for blood 
pressure among haemodialysis patients is home 
blood pressure monitoring — HBPM. This method 
is also characterized by low cost and great simplicity 
but patients have to be instructed in the appropriate 
usage of this method of measurement. Self-inflating 
automatic and semi-automatic oscillometric devices 
with shoulder cuff are recommended. Only the 
devices with proven accuracy should be used and 
patients should be advised to write down the mea-
surements [48]. The measurements should be taken 
twice a  day on days without haemodialysis. Every 
time the blood pressure measurements should be 
performed in a quiet room, with the patient in seated 
position, back and arm supported, after 5 minutes 
of rest and with two measurements per occasion 
taken 1–2 minutes apart [18]. Then, the arithmetic 
average of measurements from several days should 
be calculated [48, 49]. Among the advantages of 
this method low cost and great simplicity, as well 
as the ability to reliably identify hypertension and 
prognostic value of the risk of organ complications 
should be mentioned. Individual measurements 
(home BP monitoring) taken between haemodialysis 
have a prognostic value in assessing the risk of target 
organ damage and prognostic significance [42]. They 
are also characterized by high sensitivity (~80%) and 
high specificity (~84%) in the diagnosis of hyperten-
sion [45]. Thus, the diagnosis and treatment of hy-
pertension should be primarily guided by the results 
of the home blood pressure monitoring performed 
between haemodialysis sessions.
diagnosis of hypertension and 
target-values of blood pressure in 
haemodialysis patients
There are number of published guidelines (e.g. the 
guidelines of European Society of Hypertension [48] 
or Polish Society of Hypertension [49]) that can be 
used in the clinical practice for blood pressure con-
trol in the non-dialysis-dependent CKD population. 
However, there are no clearly defined guidelines for 
hypertensive patients in the haemodialysis popula-
tion [50–52]. 
Hypertension in haemodialysis patients should 
be defined on the basis of home BP or ABPM mea-
surements. Thresholds and methods are defined by 
the ASH/ASN (American Society of Hypertension/ 
/American Society of Nephrology) [53], the EURE-
CA-m (European Renal and Cardiovascular Medi-
cine) working group of ERA-EDTA (The European 
Renal Association — European Dialysis and Trans-
plant Association) [54] and the relevant ESH (Euro-
pean Society of Hypertension) Guidelines [55–57]. 
According to these recommendations hypertension 
in haemodialysis patients should be diagnosed on the 
basis of HBPM if an average BP ≥ 135/85 mmHg 
for measurements done in the morning and in the 
evening over 6 non-dialysis days (covering a period 
arterial hypertension 2017, vol. 21, no. 4
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of 2 weeks) is observed [48, 49, 18]. Hypertension 
in HD patients should be also defined on the basis 
of ABPM if an average BP ≥ 130/80 mmHg over 
44-hour monitoring, covering the whole mid-week 
dialysis interval, is observed [42, 18]. For haemodia-
lysis patients no recommendations can be made on 
the basis of pre- or post-dialysis BP [18]. 
The thresholds for blood pressure targets in CKD 
patients treated with haemodialysis are still matter 
of debates. Agarwal et al. (2010) reported that the 
lowest risk of death is found in patients with HBPM 
SBP 120–130 mmHg [58]. Therefore it might be 
concluded that the target systolic blood pressure 
measured between haemodialysis sessions (HBPM) 
seems to be similar to general population, this means 
< 135 mmHg [48, 41].
Antihypertensive treatment in patients 
with chronic kidney disease on 
haemodialysis
Treatment methods of hypertension can be di-
vided into three groups: non-pharmacological, 
pharmacological and invasive/surgical. Among the 
non-pharmacological methods of antihypertensive 
treatment in patients with chronic kidney disease on 
haemodialysis reducing volaemia, reducing sodium 
intake from dialysate or in the diet, should be listed. 
Reducing volaemia can be achieved in two ways. 
First, by reducing dry weight, what can be done by 
haemodialysis with increased ultrafiltration. Second-
ly, by reducing sodium intake, attained both by re-
ducing the concentration of sodium in the dialysate 
and the use of a  low sodium diet. Non-pharmaco-
logical interventions targeting sodium and volume 
excess are fundamental for BP reduction in this pop-
ulation and should be carefully implemented before 
pharmacological interventions [18]. 
Non-pharmacological methods — reducing 
volaemia
Conceptually, slow reduction in estimated dry 
weight over time with little change in interdialy-
tic weight gain could lower blood pressure without 
imposing excessive dietary restrictions on patients. 
Gradual dry weight reduction leads to the improved 
ambulatory blood pressure in hypertensive haemodia - 
lysis patients [59]. Techniques that monitor blood 
volume during haemodialysis may offer opportunity 
to better estimate dry weight in haemodialysis pa-
tients. The relation between dry-weight reduction and 
hypertension is well described in a randomized trial 
DRIP (Dry-Weight Reduction in Hypertensive Hae-
modialysis Patients) [59]. In this study standard ultra-
filtration and additional ultrafiltration 0.1 kg/10 kg 
of weight were compared in 150 haemodialysis pa-
tients with hypertension during the eight-week fol-
low-up. As a consequence, respectively weight loss of 
1 kg and no decrease in body weight were observed. 
The weight loss of 1 kg was related to lowering blood 
pressure of 7/3 mmHg [59]. On the other hand, in 
another study looking at the potential long-term 
effects of volume status, as assessed by relative plas-
ma slope (flatter indicating volume overload) during 
haemodialysis treatment, it was showed that volume 
overload was associated with increased mortality in-
dependently on ultrafiltration rate [59–63]. 
Another non-pharmacological method of antihy-
pertensive treatment in haemodialysis patients is the 
reducing sodium intake achieved by reduction of so-
dium concentration in dialysate. Movilli et al. found 
a positive sodium balance during haemodialysis pro-
cedure in 72% haemodialysis patients with chronic 
kidney disease [64]. Relatively high dialysate sodium 
concentration (with sodium concentration equal 
140 mmol/l) causes decreased sodium removal, which 
leads to volume overload and then to hypertension. 
Moreover, use of high sodium concentration in the 
dialysate results in the increase of serum sodium con-
centration, which leads to increased thirst and, as 
a consequence, to the volume overload and finally to 
hypertension [65]. De Paula et al. observed decreases 
of blood pressure due to individualization of sodium 
concentration in dialysate, equal to that found before 
3 previous haemodialysis procedures [66]. 
Another method of reducing sodium intake is 
based on low sodium diet. Magden et al. found 
SBP decrease from 147 mmHg to 119 mmHg in 15 
haemodialysis patients with chronic kidney disease 
using low sodium diet [67]. Moreover, Maduell et 
al. reported the decrease of blood pressure from 139/ 
/79 mmHg to 132/75 mmHg in 15 haemodialysis pa-
tients with chronic kidney disease in response to salt 
reduction from 10.2 g to 7.1 g per day [68]. Current 
daily intake of salt in Poland is around 14.2 g, which 
is three times more than the WHO recommendation 
amounting to 5–6 g per day. Many sources of sodium 
in the diet could be mentioned. Sodium is a natural 
component of animal food products, component of 
salt used for seasoning meals and addition to pro-
cessed food (which is about 85% of sodium intake). 
Among food with extremely high sodium content, is 
instant soup (1.9 g — i.e. 2.4 g of salt in one por-
tion), instant noodle soup (2.8 g — i.e. 4.1 g of salt/ 
/portion), pizza (7 g — i.e. 12.8 g of salt), Chinese 
food (5.5 g — i.e. 11 g of salt), Indian food (3.6 g — 
i.e. 6.1 g of salt), kebab (4 g — i.e. 8.4 g of salt) and 
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fast food. Meal in fast food restaurants are composed 
by sandwich, fries and sauce consists of 4.5 g of salt 
which represents 90% of the daily recommended 
salt intake [69–71]. Daily sodium intake in haemo-
dialysis patients should be limited to 65 mmol (i.e. 
1.5 g of sodium or 4 g of sodium chloride) [18]. To 
achieve this, it is advisable to discontinue the use of 
salt as a  seasoning of meals, preparing dishes with 
natural and fresh products and avoiding processed 
food [69–71].
Renal denervation
Renal denervation is the interventional method 
currently recommended in selected patients with 
resistant hypertension. Schlaich et al. in prelimi-
nary study described 9 haemodialysis patients with 
CKD treated by this method using Simplicity cathe-
ter. In this study, decrease of systolic blood pressure 
from 171 mmHg to 138 mmHg was identified 12 
months after the renal denervation procedures [72]. 
Additionally, Hoye et al. described 9 dialysis patients 
(6 treated by haemodialysis, 3 by peritoneal dial-
ysis) with chronic kidney disease and resistant hy-
pertension treated with EnligHTNTM catheter. In 
this study, decrease of systolic blood pressure from 
179 mmHg to 154 mmHg and decrease of SBP in 
ABPM from 173 mmHg to 152 mmHg were observed 
12 months after renal denervation procedures [73]. 
To define the role of renal denervation in the hy-
pertension treatment among haemodialysis patients 
further studies with sham procedures, higher number 
of participants and longer follow-ups are needed.
Pharmacotherapy
Two meta-analysis suggest that antihypertensive 
therapy (including b-adrenergic antagonists, angio-
tensin converting enzyme inhibitors [ACEIs], angio-
tensin II receptor blockers [ARBs], calcium channel 
blockers [CCBs] and mineralocorticoid receptor 
antagonists [MRAs]) positively influenced on the 
prognosis in the haemodialysis patients. The major 
finding of meta-analysis performed by Agarwal et 
al. [74] is that the overall benefit of antihyperten-
sive therapy compared with the control (or place-
bo) group reduced the combined hazard ratio for 
cardiovascular events by 31% using a  fixed-effects 
model and by 38% using a  random-effects model. 
There was substantial heterogeneity between studies 
with respect to outcomes. However, when studies 
were divided based on inclusion of normotensive 
subjects in the randomized group, it explained most 
of between-study variance. Heterogeneity between 
normotensive and hypertensive groups was highly 
significant (p = 0.006). Although the hypertensive 
group had a pooled hazard ratio of 0.49 (95% CI: 
0.35 to 0.67), the normotensive group had a pooled 
hazard ratio of 0.86 (95% CI: 0.67 to 1.12). In fact, 
even all-cause mortality, an outcome most common-
ly measured in the observational studies, was not 
increased with treatment. While, in a meta-analysis 
by Heerspink et al. [75] it was shown that treatment 
with agents that lower blood pressure reduces car-
diovascular morbidity and mortality in patients on 
maintenance dialysis. The effects are consistent with 
or without the presence of hypertension and other 
comorbidities and across a range of drug classes. Fur-
thermore, this analysis is not able to separate out the 
effects of blood pressure lowering for specific drug 
classes. The results do not show any differences in 
cardiovascular events caused by different drug classes. 
The data suggest that drugs inhibing renin-angio-
tensin-system activity, b-adrenergic antagonists, and 
calcium-channel blockers are all suitable for use in 
patients on dialysis
The selection of appropriate antihypertensive 
pharmacotherapy in haemodialysis patients is still 
matter of debate. Some arguments in this debate 
come from the results of HDPAL study [76]. The 
purpose of HDPAL — randomized, controlled tri-
al was to determine among maintenance haemo-
dialysis patients with left ventricular hypertrophy 
assessed by echocardiography and hypertension, 
whether b-adrenergic antagonists-based antihyper-
tensive therapy was more effective than angiotensin 
converting enzyme-inhibitor-based antihyperten-
sive therapy in causing a  greater regression of left 
ventricular hypertrophy. In this study subjects were 
randomly assigned to either open label lisinopril 
(n = 100) or atenolol (n = 100), each administered 
three times per week after dialysis. Monthly moni-
tored home blood pressure (BP) was controlled to 
< 140/90 mmHg with dry weight adjustment and 
sodium restriction. If the blood pressure target was 
not achieved calcium channel blockers and subse-
quently doxazosin, minoxidil and guanfacine were 
added. The primary outcome was the change in left 
ventricular mass index (LVMI) from baseline, to 
12 months. Among hypertensive patients with left 
ventricular hypertrophy on maintenance haemodia-
lysis, in the HDPAL trial, treatment based on either 
atenolol or lisinopril produced statistically and cli-
nically significant reductions in BP from baseline 
that was sustained over the 12-month course of the 
trial. Despite a greater reduction in dry weight, com-
pared with atenolol, the administration of lisinopril 
was associated with an increased risk of hospital-
izations for congestive heart failure. In addition, 
lisinopril therapy was associated with an increased 
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risk of all-cause hospitalizations and cardiovascular 
morbidity. Specifically, lisinopril administration was 
also associated with an increased incidence of the 
combined risk of hospitalizations due to congestive 
heart failure, myocardial infarction, strokes and car-
diovascular death. Furthermore, this therapy was also 
associated with an increased risk of hyperkalemia and 
emergent treatment for hypertensive crises. It seems 
then HDPAL trial shows that atenolol-based antihy-
pertensive therapy is superior compared with lisino-
pril-based therapy in haemodialysis patients. Despite 
both groups being targeted to home BP of < 140/ 
/90 mmHg at each monthly visit, the lisinopril-based 
group required a statistically greater number of an-
tihypertensive drugs and a greater need for lowering 
dry weight to lower BP. Moreover, in the lisinopril 
group, BP lowering remained numerically less using 
ambulatory BP monitoring and statistically less when 
assessed by home BP monitoring. Atenolol-based 
therapy may therefore have conferred cardiovascular 
protection by improving BP control. The conclusion 
from this study is that an initial strategy using aten-
olol (b-adrenergic antagonist therapy) is superior to 
ACE-inhibitor-based therapy, among haemodialysis 
patients with hypertension and left ventricular hy-
pertrophy. In another study, Cice et al. observed that 
carvedilol reduces mortality compared with placebo 
in HD patients with dilated cardiomyopathy [77].
What is interesting, in haemodialysis patients not 
only typical antihypertensive drugs could reduce blood 
pressure. Kuczera et al. [27] observed the decrease 
of blood pressure in 58 haemodialysis patients with 
chronic kidney disease and secondary hyperparathy-
roidism treated with calcimimetic cinacalcet. Decrease 
an average of 7 mmHg of systolic blood pressure and 
an average of 2 mmHg of diastolic blood pressure after 
6 months of cinacalcet therapy was described. These 
observations was recently confirmed by the analysis of 
results from the EVOLVE study [28].
Conclusions
•	 Patients with chronic kidney disease treated with 
haemodialysis are characterized by higher pre-
valence of hypertension and higher variability in 
blood pressure than the general population. The 
main reasons for this variability are changes in 
volaemia.
•	 In the diagnosis and treatment of hypertension 
in haemodialysis patients with chronic kidney 
disease self-measured blood pressure at home 
done between haemodialysis sessions should be 
considered.
•	 Self-measured systolic blood pressure between 
120 to 130 mmHg is associated with the best 
prognosis in haemodialysis patients with chronic 
kidney disease.
•	 Reduction of the volaemia by increasing ultrafil-
tration during haemodialysis procedures, indivi-
dualization of sodium concentration in the dialysis 
fluid and low sodium diet are the most important 
methods in the treatment of hypertension in hae-
modialysis patients with chronic kidney disease.
•	 The use of antihypertensive pharmacotherapy in 
haemodialysis patients with chronic kidney di-
sease reduces mortality in this group of patients.
•	 The drugs of first-line in hypertension treatment 
in haemodialysis patients with chronic kidney 
disease seem to be b-adrenergic antagonists.
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